Purpose: To investigate whether patients who are on alfa 1-AR antagonists for the treatment of benign prostatic hyperplasia (BPH) had better results after shock wave lithotripsy (SWL).
Patients and Method: We retrospectively reviewed the records of male patients older than 50 years and underwent SWL. Clinical characteristics including the use of alfa 1-AR antagonists for BPH were analyzed. Mann Whitney-U test was used for data not normally distributed and student's t test for data normally distributed. The categorical variables were analyzed by the Chi-square test. A multiple logistic regression analysis was used to analyze the associations of variables on successful treatment.
Results: A total of 264 renal units were treated. Complete stone clearance was achieved in 167 RUs (63.3%) and 28 RUs (10.6%) had CIRF. In 69 RUs (26.1%) SWL failed. More patients were on alfa 1-AR antagonists for BPH in the successfully treated group (p=0.028). The multivariate analysis revealed that use of alfa 1-AR antagonists had significant effects on the success of SWL (p=0.047). SWL was performed to 34 RUs of 33 patients who were on alfa 1-AR antagonists and it was successful in 30 RUs (88.2%) In the remaining 230 RUs stone-free state was achieved in 165 RUs (71.7%) (p=0.028). Stone free rates were similar for patients on alfuzosine, tamsulosine, and doxazosine (p=0.310).
Conclusion: Patients who are being treated with alfa 1-AR antagonist agents for BPH have better results after SWL treatment, compared to patients not receiving alfa 1-AR antagonist. The improved results are independent of the type of alfa 1-AR antagonist.
Written by:
Gul U, Yaycioglu O Md Febu, Kuzgunbay B, Sariturk C, Kayra MV, Ozkardes H. Are you the author?
Baskent University, Urology, dadaloglu mah, yuregir, Adana, Turkey, 01250.
Reference: J Endourol. 2012 Dec 13. Epub ahead of print.
doi: 10.1089/end.2012.0630
PubMed Abstract
PMID: 23237326
UroToday.com Endourology Section
